How long a person can usually live with targeted therapy for lung cancer is related to the type of gene mutation of lung cancer, whether it is sensitive to targeted drugs, etc., and needs to be analyzed on a case-by-case basis. At present, targeted therapy for advanced non-small cell lung cancer has the most research and the fastest progress. Before targeted drugs became available, the survival of advanced lung cancer was about 1 year, but nowadays the median survival of patients with sensitive mutations who receive regular targeted therapy can reach about 4 years for those with golden mutations. Appropriate genetic testing must be performed before targeted drug therapy to find out if there is a driver gene mutation, and only those with sensitive mutations can undergo targeted therapy. If there is an EGFR gene mutation, gefitinib and erlotinib can be taken, and the median survival time is about 2 years. If there is a T790 gene mutation, take targeted drug therapy such as ositinib, the median survival time can be more than 30 months. If there is a gene mutation such as ALK, taking crizotinib treatment, the median survival time can also reach more than 30 months. In addition, in the process of targeted therapy, patients need to follow the doctor’s instructions to take medication on time, pay attention to a light diet, nutrition, eat more food containing high-quality protein, as well as fresh fruits and vegetables. At the same time, patients also need to have regular checkups to check the bone marrow function, liver and kidney function.